溃疡性结肠炎低级别上皮内瘤变进展风险预测工具的多中心验证
该研究基于英国四中心2001-2019年成人溃疡性结肠炎(UC)低级别上皮内瘤变(LGD)患者回顾性队列,发现队列246例构建Cox模型,外部验证198例。四个临床病理变量与进展为晚期肿瘤(AN)显著相关,模型校准良好(O/E=1.01),并转化为在线工具UC-CaRE。
要点
- 内镜下可见LGD>1cm、不可切除或内镜切除不完全、LGD诊断5年内中重度组织学炎症、多灶性是AN独立预测因子。
- 四变量模型在验证队列中总体校准O/E=1.01(95%CI 0.64-1.52),最低风险组13年随访特异性100%。
- 基于UC-CaRE在线工具可计算患者个体化AN风险,辅助治疗决策。
核心结论
- 多队列验证证实,大范围、未切除、多灶性LGD且近期中重度炎症的UC患者进展为AN风险最高。
- 个体化风险预测可通过UC-CaRE工具提供,支持治疗决策。
研究设计与样本
- 回顾性多中心验证队列研究,成人UC患者以LGD为索引诊断,来自英国四个中心,2001-2019年随访至进展为AN。
- 发现队列n=246,使用Cox回归从临床病理特征推导多变量风险预测模型;验证队列来自三个外部中心n=198。
主要发现
- 内镜下可见LGD>1cm与AN进展相关(HR 2.7;95%CI 1.2-5.9)。
- 不可切除或内镜切除不完全与AN进展相关(HR 3.4;95%CI 1.6-7.4)。
- LGD诊断5年内中重度组织学炎症与AN进展相关(HR 3.1;95%CI 1.5-6.7)。
- 多灶性与AN进展相关(HR 2.9;95%CI 1.3-6.2)。
- 验证队列中模型总体校准O/E=1.01(95%CI 0.64-1.52),最低风险组13年随访特异性100%。
关键数值与推荐
- 风险预测模型包含四个变量:内镜下可见LGD>1cm、不可切除或内镜切除不完全、LGD诊断5年内中重度组织学炎症、多灶性。
- 模型在验证队列中总体校准O/E=1.01(95%CI 0.64-1.52)。
- 最低风险组在13年可用随访期内特异性达100%。
临床怎么用
- 对UC合并LGD患者,评估LGD大小、可切除性、多灶性及近期组织学炎症程度以分层AN风险。
- 可使用UC-CaRE在线工具(www.UC-CaRE.uk)计算个体化风险,辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with ulcerative colitis (UC) diagnosed with low-grade dysplasia (LGD) have increased risk of developing advanced neoplasia (AN: high-grade dysplasia or colorectal cancer). We aimed to develop and validate a predictor of AN risk in patients with UC with LGD and create a visual web tool to effectively communicate the risk. DESIGN: In our retrospective multicentre validated cohort study, adult patients with UC with an index diagnosis of LGD, identified from four UK centres between 2001 and 2019, were followed until progression to AN. In the discovery cohort (n=246), a multivariate risk prediction model was derived from clinicopathological features using Cox regression. Validation used data from three external centres (n=198). The validated model was embedded in a web tool to calculate patient-specific risk. RESULTS: Four clinicopathological variables were significantly associated with AN progression in the discovery cohort: endoscopically visible LGD >1 cm (HR 2.7; 95% CI 1.2 to 5.9), unresectable or incomplete endoscopic resection (HR 3.4; 95% CI 1.6 to 7.4), moderate/severe histological inflammation within 5 years of LGD diagnosis (HR 3.1; 95% CI 1.5 to 6.7) and multifocality (HR 2.9; 95% CI 1.3 to 6.2). In the validation cohort, this four-variable model accurately predicted future AN cases with overall calibration Observed/Expected=1.01 (95% CI 0.64 to 1.52), and achieved 100% specificity for the lowest risk group over 13 years of available follow-up. CONCLUSION: Multicohort validation confirms that patients with large, unresected, multifocal LGD and recent moderate/severe inflammation are at highest risk of developing AN. Personalised risk prediction provided via the Ulcerative Colitis-Cancer Risk Estimator ( www.UC-CaRE.uk ) can support treatment decision-making.
引用
- Curtius K, Kabir M, Al Bakir I, et al. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut. 2021. PMID: 33990383. doi:10.1136/gutjnl-2020-323546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。